CNS Drugs

, Volume 27, Issue 2, pp 155–161 | Cite as

Newly Initiated Opioid Treatment and the Risk of Fall-Related Injuries

A Nationwide, Register-Based, Case-Crossover Study in Sweden
  • Karin C. Söderberg
  • Lucie Laflamme
  • Jette Möller
Original Research Article



There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients.


The objective of this study was to assess the short-term effects of newly prescribed opioids on the risk of fall-related injuries in the general adult population.


A case-crossover design was applied on national register data linking, at the individual level, fall-injury information involving adults aged 18 years and above identified in the Swedish National Inpatient Register (during the period 1 May 2006 to 31 December 2009) and dispensed drugs from the Swedish Prescribed Drug Register (n = 167,257 cases with a first fall-related injury). All types of opioid substances were considered, classified according to the Anatomical Therapeutic Chemical (ATC) classification system. We investigated newly dispensed opioids 28 days preceding the injury, compared with an earlier, and equally long, control period following a 3-month washout period. Conditional logistic regression was used to estimate odds ratio (OR) and 95 % confidence interval (CI). The analyses were also conducted stratified by age group, by type of fall and for each period of 1 week during the 28-day period.


From among the fall-injured patients, 7,450 patients (4.5 %) had a new opioid dispensation within 28 days prior to the injury, of which the most frequent types were tramadol (2.0 %) and codeine (1.1 %). Consistently increased risks of fall-related injuries associated with a new prescription of any opioid were found and they were most pronounced among young adults, 18–29 years of age (OR, 7.17; 95 % CI 5.04–10.2). The closer the dispensation date to the injury, the higher the odds: an OR of 5.14 (95 % CI 4.76–5.55) during the first week of opioid treatment and 1.23 (95 % CI 1.10–1.38) for the fourth week. Of the documented falls, the risk was most pronounced for falls from ‘another, high level’ (OR, 5.33; 95 % CI 3.99–7.10).


Newly prescribed opioids may trigger injurious falls. The effect lowers over time and is less pronounced with increasing age. The risk is also higher for fall from height.


Femur Neck Tramadol Hydromorphone Case Period Unintentional Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors report no conflicts of interest in this work. This project has approval from the Regional Ethical Review Board in Stockholm. The study forms part of the research projects granted by the Swedish Civil Contingencies Agency and by the Swedish Research Council. None of the funding organizations have had any influence on the design and conduct of the study; the collection, management, analysis or interpretation of the data; or the preparation, review or approval of the manuscript.


  1. 1.
    The National Board of Health and Welfare. Systematiskt arbete för äldres säkerhet, om fall, trafikolyckor och bränder. The National Board of Health and Welfare: Stockholm; 2007.Google Scholar
  2. 2.
    The National Board of Health and Welfare. Indikatorer för god läkemedelsterapi hos äldre. The National Board of Health and Welfare: Stockholm; 2010.Google Scholar
  3. 3.
    The National Board of Health and Welfare. Statistical database of health and medical care (online). Accessed 17 Apr 2012.
  4. 4.
    Okie S. A flood of opioids, a rising tide of deaths. New Engl J Med. 2010;363(21):1981–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Walwyn WM, Miotto KA, Evans CJ. Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions. Drug Alcohol Depend. 2010;108(3):156–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Friedrich MJ. Research yields new insights into mechanisms and treatment of pain. JAMA. 2012;307(3):239–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Lovell SJ, Taira T, Rodriguez E, et al. Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. Acad Emerg Med. 2004;11(12):1278–82.PubMedGoogle Scholar
  8. 8.
    Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62(10):1172–81.PubMedCrossRefGoogle Scholar
  9. 9.
    von Meyer L. Opioids and driving ability (in German). MMW Fortschr Med. 2006;148(18):33–4.Google Scholar
  10. 10.
    Buckeridge D, Huang A, Hanley J, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010;58(9):1664–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Coben JH, Davis SM, Furbee PM, et al. Hospitalizations for poisoning by prescription opioids, sedatives, and tranquilizers. Am J Prev Med. 2010;38(5):517–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Green TC, Grau LE, Carver HW, et al. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997–2007. Drug Alcohol Depend. 2011;115(3):221–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Reith D, Fountain J, Tilyard M. Opioid poisoning deaths in New Zealand (2001–2002). N Z Med J. 2005;118(1209):U1293.PubMedGoogle Scholar
  14. 14.
    Leung SY. Benzodiazepines, opioids and driving: an overview of the experimental research. Drug Alcohol Rev. 2011;30(3):281–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Kelly KD, Pickett W, Yiannakoulias N, et al. Medication use and falls in community-dwelling older persons. Age Ageing. 2003;32(5):503–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Baranzini F, Diurni M, Ceccon F, et al. Fall-related injuries in a nursing home setting: is polypharmacy a risk factor? BMC Health Serv Res. 2009;9:228.PubMedCrossRefGoogle Scholar
  17. 17.
    Kallin K, Gustafson Y, Sandman PO, et al. Drugs and falls in older people in geriatric care settings. Aging Clin Exp Res. 2004;16(4):270–6.PubMedGoogle Scholar
  18. 18.
    Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163(8):949–57.PubMedCrossRefGoogle Scholar
  19. 19.
    Ebly EM, Hogan DB, Fung TS. Potential adverse outcomes of psychotropic and narcotic drug use in Canadian seniors. J Clin Epidemiol. 1997;50(7):857–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Guo Z, Wills P, Viitanen M, et al. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol. 1998;148(9):887–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Walker PC, Alrawi A, Mitchell JF, et al. Medication use as a risk factor for falls among hospitalized elderly patients. AJHP. 2005;62(23):2495–9.PubMedGoogle Scholar
  22. 22.
    Weiner DK, Hanlon JT, Studenski SA. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology. 1998;44(4):217–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Moden B, Merlo J, Ohlsson H, et al. Psychotropic drugs and falling accidents among the elderly: a nested case control study in the whole population of Scania, Sweden. J Epidemiol Comm Health. 2010;64(5):440–6.CrossRefGoogle Scholar
  24. 24.
    Moden B, Ohlsson H, Merlo J, et al. Psychotropic drugs and accidents in Scania, Sweden. Eur J Public Health. 2012;22(5):726–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260(1):76–87.PubMedCrossRefGoogle Scholar
  26. 26.
    Shorr RI, Griffin MR, Daugherty JR, et al. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992;47(4):M111–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Neutel CI, Hirdes JP, Maxwell CJ, et al. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25(4):273–8.PubMedCrossRefGoogle Scholar
  28. 28.
    McQuay H. Opioids in pain management. Lancet. 1999;353(9171):2229–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.PubMedGoogle Scholar
  30. 30.
    Maclure M, Mittleman MA. Should we use a case-crossover design? Ann Rev Public Health. 2000;21:193–221.CrossRefGoogle Scholar
  31. 31.
    Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335–6.PubMedGoogle Scholar
  32. 32.
    Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(Suppl. 3):S51–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009;18(1):53–65.PubMedCrossRefGoogle Scholar
  34. 34.
    The National Board of Health and Welfare. The national patient register (NPR) (online). Accessed 21 May 2012.
  35. 35.
    Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–35.PubMedCrossRefGoogle Scholar
  36. 36.
    WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system, structure and principles (online). Accessed 17 Apr 2012.
  37. 37.
    Handoko KB, Zwart-van Rijkom JE, Hermens WA, et al. Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiol Drug Saf. 2007;16(2):189–96.PubMedCrossRefGoogle Scholar
  38. 38.
    Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 1999;21(2):101–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Loeber S, Nakovics H, Kniest A, et al. Factors affecting cognitive function of opiate-dependent patients. Drug Alcohol Depend. 2012;120(1–3):81–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl). 2003;170(3):242–54.CrossRefGoogle Scholar
  41. 41.
    Bergstrom MF, Byberg L, Melhus H, et al. Extent and consequences of misclassified injury diagnoses in a national hospital discharge registry. Inj Prev. 2011;17(2):108–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.PubMedCrossRefGoogle Scholar
  43. 43.
    Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122(10):961 e7–13.Google Scholar
  44. 44.
    Morris LS, Schulz RM. Patient compliance: an overview. J Clin Pharm Ther. 1992;17(5):283–95.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Karin C. Söderberg
    • 1
    • 2
  • Lucie Laflamme
    • 1
  • Jette Möller
    • 3
  1. 1.Division of Global Health/IHCAR, Department of Public Health Sciences, Karolinska InstitutetStockholmSweden
  2. 2.Department of Clinical Pharmacology C1:68Karolinska University Hospital HuddingeStockholmSweden
  3. 3.Division of Public Health Epidemiology, Department of Public Health Sciences, Karolinska InstitutetStockholmSweden

Personalised recommendations